Addressing the Gap Between Biology and Treatment
The Unmet Need
Despite major advances in medicine, many patients with neuropsychiatric disorders experience limited treatment effectiveness or significant side effects. Increasing evidence shows that the gut microbiome plays a key role in brain function, drug metabolism, and treatment response.
AI Precision
Our AI algorithms analyze complex metagenomic data to predict precise adjuvant therapy approaches to improve brain health.
Scientific Holistic Approach
We address the ignored microbiome-gut-brain axis, integrating the patient's biological data into a comprehensive care model for brain health.
Biology-Driven Innovation
Our mission is to transform healthcare by unlocking the therapeutic potential of the human microbiome. Through personalized and scientifically grounded solutions, we aim to improve treatment precision, enhance patient outcomes, and advance a more systemic, biology-driven model of medicine.
Explore NeuroBiome
Navigate to the section most relevant to you.
For Patients
Understand how microbiome profiling can support your treatment journey.
For Clinicians
Discover precision tools designed to enhance neuropsychiatric practice.
For Investors
Explore the market opportunity and NeuroBiome's path to scale.
Founded in 2026
NeuroBiome is founded with a simple but powerful idea: every patient is biologically unique, and medicine should reflect that reality.
Growing scientific evidence indicates that the human microbiome plays a crucial role in health, influencing brain function, metabolism, immune responses, and even the efficacy of many medications. Yet this vast biological ecosystem remains largely untapped in clinical practice.
NeuroBiome was created to bridge this gap. By combining advances in microbiome science, bioinformatics, and precision medicine, we aim to translate microbiome data into actionable therapeutic insights that support clinicians and improve patient outcomes.
Our Values
Scientific Integrity
Evidence-based methodologies and measurable outcomes drive all R&D. We prioritize transparency and clinical validation.
Innovation with Purpose
We innovate to address unmet needs in brain health, ensuring every advancement generates tangible patient improvements.
Ethical Responsibility
Committed to data privacy and fairness, recognizing the profound implications of microbiome and AI insights.
Holistic Medicine
We view the gut–brain axis as a dynamic network, embracing a systems-biology perspective of health.
Long-Term Impact
Moving from symptom management to mechanism-based interventions for a sustainable transformation of brain health.
Where We're Headed
"We envision a future where the microbiome signature becomes a standard component of clinical decision-making."
In this future, treatments will no longer rely solely on generalized protocols but will instead be informed by each individual's biological ecosystem, enabling more precise, effective, and personalized healthcare.
Meet Our Team
Jessica Perego, PhD
CEO, Founder & Lead Scientist
Expert in microbiome science and neuroactive metabolites with a vision to bridge the gap between microbiome-gut-brain science and clinical neuropsychiatry.
Bioinformatics Team
Data Intelligence
Developing machine learning models to identify functional pathways in complex metagenomic datasets.
Strategic Partnership
Platform development and clinical cohort validation phases performed in a strategic partnership with Minutia.ai.
Where We Are Now
NeuroBiome is currently in its foundational phase — building the AI platform, validating clinical protocols, and establishing early clinical partnerships. Here is our development roadmap.
The Pipeline Workflow
Three-Step Precision Platform
High-Resolution Profiling
- Shotgun Metagenomics for 99.9% taxonomic accuracy.
- Deep functional profiling of the microbial ecosystem.
- Identification of core neuroactive metabolites.
AI Predictive Model
- Predicts causal links between microbiome and neurological outcomes.
- Simulates targeted microbial modulation in silico.
- Continuous refinement fueled by longitudinal patient follow-up and our growing global database.
Targeted Intervention
- Patient-specific modulation to restore correct gut-brain signaling.
- Precision formulation of microbial adjuvants.
- Monitoring and iterative therapeutic adjustment.
Who Is It Dedicated To?
Our microbiome adjuvant therapy is specifically designed for individuals with neurological or psychiatric conditions. We focus on those who are currently looking for a more comprehensive, biological approach to wellness. Our technology is dedicated to addressing:
Neurological Diseases
Alzheimer's, Parkinson's, and Multiple Sclerosis.
Psychiatric Issues
Depression, anxiety disorders, chronic stress-related conditions, and other mood disorders.
Treatment Support
Patients seeking to enhance the effectiveness of standard pharmacological interventions and/or limit conventional therapy side effects.
Expected Benefits
By reshaping microbiome composition to restore functional gut–brain axis communication, we aim to strengthen biological resilience, improve treatment response, and reduce adverse effects.
Enhanced Efficacy
Improving the effectiveness of primary medications by modulating metabolic pathways in the gut.
Symptom Stability
Reducing the frequency and intensity of clinical episodes through steady microbial neurotransmitter regulation.
Reduced Side Effects
Mitigating GI-related side effects often associated with neuropsychiatric medications.
Personalized Roadmap
Gain a precise biological understanding of your health with data-driven insights tailored to your unique microbiome signature.
The Gut–Brain Axis
The bidirectional communication highway between the gut microbiome and the brain — and why it matters for brain health, treatment response, and precision neuropsychiatry.
A Dynamic Bidirectional Network
The gut–brain axis refers to the complex communication network linking the enteric nervous system of the gastrointestinal tract with the central nervous system. This bidirectional communication occurs through neural, endocrine, immune, and metabolic pathways, allowing the gut microbiome to exert direct influence over brain function, mood regulation, neuroinflammation, and treatment response.
Trillions of microorganisms residing in the gut produce neuroactive metabolites — including short-chain fatty acids, neurotransmitters, and immune modulators — that can cross into the bloodstream and influence the brain's biochemical environment. Disruptions to this ecosystem (gut dysbiosis) have been increasingly linked to neuropsychiatric disorders including depression, anxiety, Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
Key Scientific Concepts
Microbiome–Neurotransmitter Axis
Gut bacteria produce and modulate the availability of serotonin, GABA, dopamine precursors, and other neuroactive compounds that directly impact mood, cognition, and neurological function.
Neuroinflammation & Dysbiosis
Gut dysbiosis increases intestinal permeability, allowing microbial metabolites and inflammatory signals to enter systemic circulation and trigger neuroinflammatory cascades implicated in neurodegenerative and psychiatric disease.
Pharmacomicrobiomics
Individual differences in gut microbiome composition significantly affect drug absorption, metabolism, and bioavailability — explaining variable therapeutic responses across patients receiving identical treatments.
From Microbiome Complexity to Clinical Clarity
NeuroBiome harnesses the scientific advances in gut–brain axis research through high-resolution shotgun metagenomic profiling, translating microbiome complexity into precise, clinically actionable therapeutic insights. Our AI platform transforms raw biological data into personalized intervention strategies that support existing neuropsychiatric care.
Key Scientific Publications
A curated selection of peer-reviewed research underpinning the gut–brain axis science at the foundation of NeuroBiome's approach.
Integrated metabolomic and metagenomic profiling reveals distinct signatures in treatment-naïve multiple sclerosis patients
Using shotgun metagenomic sequencing and multi-biofluid metabolomics (urine, stool, serum, and CSF), this study identifies distinct gut microbiome and metabolomic signatures in treatment-naïve MS patients at diagnosis. Key findings include dysregulation of microbially-produced short-chain fatty acids and their systemic bioavailability, linking neuroinflammation to gut microbiome alterations prior to any pharmacological intervention.
Read Preprint →Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
The largest gut microbiome study in MS to date, examining 576 MS patients and 576 genetically unrelated healthy household controls. The study identifies significantly altered bacterial taxa — including increased Akkermansia muciniphila and decreased Faecalibacterium prausnitzii — along with dysregulated metabolic pathways and differential microbiome responses to disease-modifying treatments, establishing a clear link between gut dysbiosis, MS risk, and treatment response.
Read Paper →Gut-brain nexus: Mapping multimodal links to neurodegeneration at biobank scale
A biobank-scale study integrating endocrine, metabolic, nutritional, and digestive disorder data with polygenic risk scores and plasma biomarkers to map the gut-brain nexus in Alzheimer's and Parkinson's disease. Key findings show that multiple gut-related disorders are associated with increased AD/PD risk prior to diagnosis, and that combining gut-brain axis co-occurring disorders with genetic and proteomic data substantially enhances neurodegenerative risk prediction.
Read Paper →Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
A comprehensive review (221k+ accesses, 734 citations) systematically examining the microbiota–gut–brain axis in neurodegeneration, integrating findings across Alzheimer's, Parkinson's, and other neurodegenerative disorders. The review synthesises how the vast genetic and metabolic potential of the gut microbiome influences brain health across development, aging, and disease, with particular focus on therapeutic strategies.
Read Paper →Why nurturing the gut microbiota could resolve depression and anxiety
An in-depth feature reporting on the growing clinical evidence linking gut microbiota composition to depression and anxiety, and covering early-phase clinical trials of faecal microbiota transplantation (FMT) as a treatment for treatment-resistant depression. The article outlines the promising trajectory toward large-scale trials of probiotic and microbiome-targeted psychiatric interventions.
Read Article →Multi-omics approach identifies gut microbiota variations associated with depression
A multi-omics integration study combining metagenomics, metabolomics, and clinical data to identify specific gut microbiota signatures associated with depression. The study reveals reproducible microbial and metabolic patterns linked to depressive symptoms, supporting microbiome-informed precision approaches for psychiatric intervention.
Read Paper →The effects of oral probiotic intervention on brain structure and function in human adults: a systematic review
A systematic review of 26 articles from 19 randomised, placebo-controlled trials (762 subjects) assessing oral probiotic interventions on brain structure and function using neuroimaging and electrophysiology. Probiotic intake was found to modify resting-state brain connectivity and activity, reduce engagement of brain regions during negative emotional stimulation, and improve sleep quality — providing objective neurobiological evidence for the gut–brain axis.
Read Paper →The neuroactive potential of the human gut microbiota in quality of life and depression
This landmark study demonstrates that specific gut bacteria — particularly Coprococcus and Dialister — are consistently depleted in individuals with depression, independently of antidepressant use. By mapping the neuroactive potential of the human gut microbiome through metagenomics, the authors show that microbial synthesis of GABA precursors and other neuroactive metabolites correlates with quality of life, establishing a direct link between gut microbiome composition and neuropsychiatric health outcomes.
Read Paper → (DOI: 10.1038/s41564-018-0337-x)Who Is It Dedicated To?
Our microbiome adjuvant therapy is specifically designed for individuals navigating the complexities of neurological and neuropsychiatric health — those currently undergoing treatment seeking a more comprehensive, biological approach.
Neurological Diseases
Alzheimer's, Parkinson's, and Multiple Sclerosis.
Psychiatric Issues
Depression, anxiety disorders, chronic stress-related conditions, and other mood disorders.
Treatment Support
Patients seeking to enhance standard pharmacological interventions and/or limit conventional therapy side effects.
Potential Benefits
Greater Symptom Stability
The gut and brain communicate constantly through the gut–brain axis. By helping restore a healthier balance in the gut microbiome, NeuroBiome supports more stable communication between the gut and the brain.
This balanced signaling helps support a healthier brain environment, promoting recovery processes, reducing inflammation, and maintaining proper chemical signaling in the nervous system.
Fewer Side Effects
Many medications can cause gastrointestinal discomfort and other systemic side effects. In addition, prolonged treatment can alter the balance of the gut microbiome, affecting overall physiology and gut–brain axis communication.
Our approach aims to support microbiome stability during treatment, helping reduce unwanted side effects and limit microbiome disruptions associated with prolonged medication use.
Stronger Treatment Response
The gut microbiome plays an important role in how the body absorbs and metabolizes medications. Differences in microbial composition can influence how effectively a treatment works for each individual.
By analyzing and improving microbiome balance, NeuroBiome aims to create conditions that favor optimal drug absorption and metabolism, helping treatments work more effectively.
Understand Your Biology
Our approach provides a detailed view of your gut microbiome. This insight can help you and your clinician better understand how your biological ecosystem may influence your brain health and response to treatment.
How NeuroBiome Can Help You
We complement your existing care with precise, biologically tailored interventions.
Your Unique Microbiome Profile
A simple stool sample is sequenced using advanced metagenomics, providing a high-resolution map of the trillions of microorganisms living in your gut — species, functions, and metabolic activity.
AI-Powered Analysis
Our AI platform compares your microbiome data against clinical databases to identify patterns linked to your condition, predicting which microbial interventions are most likely to benefit you specifically.
Personalized Intervention Plan
You receive a precision microbial adjuvant protocol — designed to complement your current treatment — targeting the specific gut-brain imbalances identified in your profile.
Ongoing Monitoring & Adjustment
Your microbiome is monitored over time, with regular reassessments allowing your care team to iteratively refine your intervention as your health and microbiome profiling evolves.
Frequently Asked Questions
Why NeuroBiome for Your Practice
Deep Phenotyping
Move beyond symptom scales and conventional neurological or psychiatric parameters. NeuroBiome integrates microbiome data into a comprehensive biological profile of each patient, revealing microbial patterns that may influence neuropsychiatric conditions.
Through AI-driven microbiome modeling, our platform identifies signals relevant to the patient's clinical condition and treatment response, providing clinicians with actionable insights that support a more holistic approach to patient care through personalized treatment strategies.
AI-Driven Microbiome Modeling
Our AI platform analyzes complex microbiome patterns to identify functional imbalances and microbial signatures relevant to treatment response. This modeling approach generates clinically actionable, patient-specific microbiome insights that can support personalized therapeutic strategies.
Drug–Microbiome Interaction Insights
The gut microbiome can influence how medications are absorbed, metabolized, and tolerated, shaping individual treatment response. At the same time, many pharmacological treatments can alter microbiome composition over time, affecting gut physiology and gut–brain axis signaling.
NeuroBiome helps clinicians understand these bidirectional drug–microbiome interactions, providing microbiome-informed insights that support more personalized treatment strategies and help preserve microbiome stability during long-term therapy.
Precision Clinical Support
By integrating microbiome intelligence into clinical practice, NeuroBiome helps clinicians incorporate an additional biological layer into treatment planning, supporting more precise and individualized neuropsychiatric care.
Longitudinal Monitoring
Follow patient microbiome dynamics over time, observing real biological changes as adjuvant therapy progresses and clinical outcomes evolve.
Collaborative Platform
NeuroBiome is designed to support, not replace, clinical judgment. Our tools integrate with your workflow and expand your therapeutic toolkit.
Evidence-Based Protocols
All interventions are grounded in clinical evidence and continuously validated through our growing patient cohort database.
Designed for These Clinical Fields
Psychiatry
Neurology
The Platform at a Glance
Shotgun Metagenomics
Whole-genome sequencing of all microbial DNA in a sample. Species-level resolution across bacteria, archaea, fungi, and viruses.
ML Models
Developed in partnership with Minutia.ai. Models trained on functional metagenomics data with neuropsychiatric outcome endpoints.
Clinical Decision Support
Structured clinical reports ranking intervention priority by predicted efficacy and drug-microbiome interactions.
Iterative Refinement
Models continuously improve through longitudinal follow-up data, increasing precision as the platform's global database expands.
Join Our Clinical Network
We are actively seeking clinical partnerships to validate our platform and expand our cohort database. Early-adopter clinicians will gain access to our full platform and contribute to shaping the future of precision neuropsychiatry.
What partnership includes:
- Full platform access for patient cohort
- Dedicated scientific support
- Co-authorship opportunities on publications
- Priority access to platform updates
Join the Early-Adopter Programme
Leave your details and we will reach out within 48 hours to schedule a discovery call and discuss how NeuroBiome can integrate into your practice.
The Numbers Tell the Story
Europe & North America
disorders in Europe & North America
Why NeuroBiome, Why Now
First-Mover Advantage
NeuroBiome is the first platform dedicated to integrating shotgun metagenomics, AI-driven microbiome modeling, and precision microbial adjuvant design to address neuropsychiatric disorders.
Technology
Our AI platform (developed in partnership with Minutia.ai) and growing patient database create a defensible, data-driven moat that deepens with every patient interaction.
Large Addressable Market
NeuroBiome operates at the intersection of three rapidly expanding sectors: neuropsychiatric therapeutics, precision diagnostics, and microbiome-based medicine — each representing multi-billion-dollar global markets.
Scalable Platform Model
Our AI and bioinformatics infrastructure is inherently scalable. Every new patient enriches the dataset, strengthens predictive models, and reduces the marginal cost of delivering personalized insights.
Massive Unmet Clinical Need
Neurological and psychiatric disorders are among the leading causes of disability worldwide and have a profound impact on patients' quality of life. Despite this, many patients experience limited treatment response or significant side effects.
Microbiome-informed adjuvant medicine offers a new biological lever to enhance therapeutic precision and effectiveness.
Strong Scientific Foundation
NeuroBiome is built on a rapidly advancing body of peer-reviewed research linking the gut microbiome to brain function, drug metabolism, and treatment response. Our scientific approach is grounded in deep expertise in microbiome science and neuroactive metabolites.
The Opportunity
NeuroBiome is building a platform for microbiome-informed precision medicine in neuropsychiatric disorders, with the goal of improving treatment outcomes and helping address the global burden of brain health through more personalized and holistic care.
Path to Scale
We are seeking strategic partners and early-stage investors who share our conviction that the microbiome is the next major frontier in precision medicine.
Get in Touch
Our Location
Milan, Italy
Direct Contact